Advertisement

Using Design to Connect Patients, Providers, and Researchers: A Cognitive Assessment and Monitoring Platform for Integrative Research (CAMPFIRE)

Conference paper
  • 645 Downloads
Part of the Advances in Intelligent Systems and Computing book series (AISC, volume 779)

Abstract

There is a substantial need for an accessible suite of cognitive measures to assess and monitor signs of chemotherapy-related cognitive impairment during the treatment and survivorship phases of the cancer control continuum. To address this need we designed and demonstrated a Cognitive Assessment and Monitoring Platform for Integrative Research (CAMPFIRE), a privacy-compliant software system to support the administration of cognitive assessment measures and facilitate secure provider-patient interaction.

Keywords

Patient-reported outcomes Chemotherapy-related cognitive impairment Cognitive function Cancer Neuropsychology Computerized neuropsychological assessment 

References

  1. 1.
    American Cancer Society: Cancer Facts & Figures 2016. American Cancer Society, Atlanta (2016)Google Scholar
  2. 2.
    American Cancer Society: Cancer Treatment and Survivorship Facts & Figures 2014–2015. American Cancer Society, Atlanta (2014)Google Scholar
  3. 3.
    Ahles, T.A., Root, J.C., Ryan, E.L.: Cancer - and cancer treatment-associated cognitive change: an update on the state of the science. J. Clin. Oncol. 30(30), 3675–3686 (2012).  https://doi.org/10.1200/JCO.2012.43.0116CrossRefGoogle Scholar
  4. 4.
    Ono, M., Ogilvie, J.M., Wilson, J.S., Green, H.J., Chambers, S.K., Ownsworth, T., Shum, D.H.K.: A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Neuro-Oncology 5, 59 (2015).  https://doi.org/10.3389/fonc.2015.00059CrossRefGoogle Scholar
  5. 5.
    Wefel, J.S., Schagen, S.B.: Chemotherapy-related cognitive dysfunction. Curr. Neurol. Neurosci. Rep. 12(3), 267–275 (2012).  https://doi.org/10.1007/s11910-012-0264-9CrossRefGoogle Scholar
  6. 6.
    Ahles, T.A., Saykin, A.J., Furstenberg, C.T., Cole, B., Mott, L.A., Skalla, K., Whedon, M.B., Bivens, S., Mitchell, T., Greenberg, E.R., Silberfarb, P.M.: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 20(2), 485–493 (2002)CrossRefGoogle Scholar
  7. 7.
    Collins, B., Mackenzie, J., Stewart, A., Bielajew, C., Verma, S.: Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psycho-Oncology 18(2), 134–143 (2009).  https://doi.org/10.1002/pon.1379CrossRefGoogle Scholar
  8. 8.
    Yamada, T.H., Denburg, N.L., Beglinger, L.J., Schultz, S.K.: Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J. Neuropsychiatry Clin. Neurosci. 22(1), 48–54 (2010).  https://doi.org/10.1176/appi.neuropsych.22.1.48CrossRefGoogle Scholar
  9. 9.
    Wefel, J.S., Saleeba, A.K., Buzdar, A.U., Meyers, C.A.: Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14), 3348–3356 (2010).  https://doi.org/10.1002/cncr.25098CrossRefGoogle Scholar
  10. 10.
    Wefel, J.S., Kesler, S.R., Noll, K.R., Schagen, S.B.: Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J. Clin. 65(2), 123–138 (2015).  https://doi.org/10.3322/caac.21258CrossRefGoogle Scholar
  11. 11.
    Janelsins, M.C., Kesler, S.R., Ahles, T.A., Morrow, G.R.: Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int. Rev. Psychiatry 26(1), 102–113 (2014). http://doi.org/10.3109/09540261.2013.864260CrossRefGoogle Scholar
  12. 12.
    Jean-Pierre, P., Johnson-Greene, D., Burish, T.G.: Neuropsychological care and rehabilitation of cancer patients with chemobrain: strategies for evaluation and intervention development. Support. Care Cancer 22(8), 2251–2260 (2014).  https://doi.org/10.1007/s00520-014-2162-yCrossRefGoogle Scholar
  13. 13.
    Hutchinson, A.D., Hosking, J.R., Kichenadasse, G., Mattiske, J.K., Wilson, C.: Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat. Rev. 38(7), 926–934 (2012).  https://doi.org/10.1016/j.ctrv.2012.05.002CrossRefGoogle Scholar
  14. 14.
    Lai, J.-S., Wagner, L.I., Jacobsen, P.B., Cella, D.: Self-reported cognitive concerns and abilities: two sides of one coin? Psycho-Oncology 23(10), 1133–1141 (2014).  https://doi.org/10.1002/pon.3522CrossRefGoogle Scholar
  15. 15.
    Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B.: International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12(7), 703–708 (2011).  https://doi.org/10.1016/S1470-2045(10)70294-1CrossRefGoogle Scholar
  16. 16.
    Jansen, C.E., Cooper, B.A., Dodd, M.J., Miaskowski, C.A.: A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support. Care Cancer 19(10), 1647–1656 (2011).  https://doi.org/10.1007/s00520-010-0997-4CrossRefGoogle Scholar
  17. 17.
    Kaiser, J., Bledowski, C., Dietrich, J.: Neural correlates of chemotherapy-related cognitive impairment. Cortex 54, 33–50 (2014).  https://doi.org/10.1016/j.cortex.2014.01.010CrossRefGoogle Scholar
  18. 18.
    van Dam, F.S., Schagen, S.B., Muller, M.J., Boogerd, W., Droogleever Fortuyn, M.E., Rodenhuis, S.: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J. Natl. Cancer Inst. 90(3), 210–218 (1998)CrossRefGoogle Scholar
  19. 19.
    Wieneke, M.H., Dienst, E.R.: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4(1), 61–66 (1995).  https://doi.org/10.1002/pon.2960040108CrossRefGoogle Scholar
  20. 20.
    Schagen, S.B., Boogerd, W., Muller, M.J., Huinink, W.T.B., Moonen, L., Meinhardt, W., Van Dam, F.S.: Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer (2008)CrossRefGoogle Scholar
  21. 21.
    Skaali, T., Fosså, S.D., Andersson, S., Cvancarova, M., Langberg, C.W., Lehne, G., Dahl, A.A.: Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress. J. Psychosom. Res. 70(5), 403–410 (2011).  https://doi.org/10.1016/j.jpsychores.2010.12.004CrossRefGoogle Scholar
  22. 22.
    Weintraub, S., Dikmen, S.S., Heaton, R.K., Tulsky, D.S., Zelazo, P.D., Bauer, P.J., Carlozzi, N.E., Slotkin, J., Blitz, D., Wallner-Allen, K., Fox, N.A., Beaumont, J.L., Mungas, D., Nowinski, C.J., Richler, J., Deocampo, J.A., Anderson, J.E., Manly, J.J., Borosh, B., Havlik, R., Conway, K., Edwards, E., Freund, L., King, J.W., Moy, C., Witt, E., Gershon, R.C.: Cognition assessment using the NIH toolbox. Neurology, 80(11 Suppl 3), S54–S64 (2013). http://doi.org/10.1212/WNL.0b013e3182872dedCrossRefGoogle Scholar
  23. 23.
    Weintraub, S., Dikmen, S.S., Heaton, R.K., Tulsky, D.S., Zelazo, P.D., Slotkin, J.6., Carlozzi, N.E., Bauer, P.J., Wallner-Allen, K., Fox, N., Havlik, R., Beaumont, J.L., Mungas, D., Manly, J.J., Moy, C., Conway, K., Edwards, E., Nowinski, C.J., Gershon, R.: The cognition battery of the NIH toolbox for assessment of neurological and behavioral function: validation in an adult sample. J. Int. Neuropsychol. Soc. JINS 20(6), 567–578 (2014).  https://doi.org/10.1017/S1355617714000320CrossRefGoogle Scholar
  24. 24.
    Cella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S., Amtmann, D., Bode, R., Buysse, D., Choi, S., Cook, K., DeVellis, R., DeWalt, D., Fries, J.F., Gershon, R., Hahn, E.A., Lai, J.-S., Pilkonis, P, Revicki, D., Rose, M., Weinfurt, K., Hays, R.: Initial adult health item banks and first wave testing of the patient-reported outcomes measurement information system (PROMISTM) network: 2005–2008. J. Clin. Epidemiol. 63(11), 1179–1194 (2010).  https://doi.org/10.1016/j.jclinepi.2010.04.011
  25. 25.
    Cella, D., Yount, S., Rothrock, N., Gershon, R., Cook, K., Reeve, B., Ader, D., Fries, J.F., Bruce, B., Rose, M.: The patient-reported outcomes measurement information system (PROMIS). Med. Care 45(5 Suppl 1), S3–S11 (2007). http://doi.org/10.1097/01.mlr.0000258615.42478.55CrossRefGoogle Scholar
  26. 26.
    Riley, W.T., Rothrock, N., Bruce, B., Christodolou, C., Cook, K., Hahn, E.A., Cella, D.: Patient-reported outcomes measurement information system (PROMIS) domain names and definitions revisions: further evaluation of content validity in IRT-derived item banks. Qual. Life Res. Int. J. Qual. Life Aspects Treat. Care Rehabil. 19(9), 1311–1321 (2010).  https://doi.org/10.1007/s11136-010-9694-5CrossRefGoogle Scholar
  27. 27.
    Cella, D., Lai, J.-S., Nowinski, C.J., Victorson, D., Peterman, A., Miller, D., Bethoux, F., Heinemann, A., Rubin, S., Cavazos, J.E., Reder, A.T., Sufit, R., Simuni, T., Holmes, G.L., Siderowf, A., Wojna, V., Bode, R., McKinney, N., Podrabsky, T., Wortman, K., Choi, S., Gershon, R., Rothrock, N., Moy, C.: Neuro-QOL brief measures of health-related quality of life for clinical research in neurology. Neurology 78(23), 1860–1867 (2012). http://doi.org/10.1212/WNL.0b013e318258f744CrossRefGoogle Scholar
  28. 28.
    O’Farrell, E., MacKenzie, J., Collins, B.: Clearing the Air: a review of our current understanding of “chemo fog”. Current Oncol. Rep. 15(3), 260–269 (2013).  https://doi.org/10.1007/s11912-013-0307-7CrossRefGoogle Scholar
  29. 29.
    Parsey, C.M., Schmitter-Edgecombe, M.: Applications of technology in neuropsychological assessment. Clin. Neuropsychol. 27(8) (2013). http://doi.org/10.1080/13854046.2013.834971CrossRefGoogle Scholar
  30. 30.
    Zhang, L., Chai, X., Ling, S., Fan, J., Yang, K., Ren, Q.: Dispersion and accuracy of simulated phosphene positioning using tactile board. Artif. Organs 33(12), 1109–1116 (2009).  https://doi.org/10.1111/j.1525-1594.2009.00826.xCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Charles River Analytics, Inc.CambridgeUSA

Personalised recommendations